Ischemia-Reperfusion Injury
Conditions
Brief summary
About 200000 cardiac operations are performed in China every year. Cardiopulmonary bypass is the basic strategy of open-heart surgery, which may lead to myocardial ischemia-reperfusion injury and low cardiac output syndrome. It will inevitably affect the patient's postoperative recovery. A number of studies have shown that dexmedetomidine, as an auxiliary sedative, has the effects of inhibiting stress response, antiarrhythmia and cardiac protection.Dexmedetomidine has been widely used in anesthesia in cardiac surgery. However, at present, few clinical studies pay attention to its mechanism. In this study, dexmedetomidine will be used in cardiac surgery with cardiopulmonary bypass to explore the mechanism of cardiac ischemia-reperfusion injury and the protective effect of dexmedetomidine.
Interventions
DRUGdexmedetomidine
The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
DRUGPlacebo
The participant will pump saline without dexmedetomidine at the same speed as group D.
Sponsors
Affiliated Hospital of Nantong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-70 years 2. American Society of Anesthesiologists(ASA) physical status of I-Ⅳ 3. BMI: 18.5-28 kg/m2 4. Type of operation: elective open-heart surgery with cardiopulmonary bypass 5. The patient and/or family members have signed the informed consent.
Exclusion criteria
1. Preoperative diagnosis of heart failure 、gradeⅡ-Ⅲ heart block and diabetes 2. LEVF\<40% 3. Severe coagulation dysfunction 4. Severe heart, lung, liver and kidney insufficiency 5. Used to have immunosuppressive therapies such as radiotherapy, chemotherapy and glucocorticoid, or have immune system diseases 6. Perioperative allogeneic blood transfusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| troponin T level | before operation | the level of troponin in the participant's serum |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AQP4、iNOS andTNF-α level | before operation | the level of AQP4、iNOS andTNF-α in the participant's serum |
Countries
China
Outcome results
None listed